Cahill Represents Envigo in Agreement to be Acquired by Inotiv
Cahill represented Envigo RMS Holding Corp. (“Envigo”), a leading provider of research models and services, in connection with its agreement to be acquired by Inotiv, Inc. (“Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. Upon consummation of the acquisition, which is subject to customary closing conditions, the combined company will enable drug developers to access products and services for the entirety of discovery and nonclinical development within one organization. Transaction consideration consists of $200 million of cash and 9,365,173 Inotiv common shares, subject to certain adjustments at closing. Upon closing of the transaction, Inotiv shareholders are expected to own approximately 64 percent and Envigo shareholders are expected to own approximately 36 percent of the combined company on a fully diluted basis.
The Cahill team representing Envigo is led by corporate partners Kimberly C. Petillo-Décossard, Jonathan A. Schaffzin and Ross E. Sturman, associates Joseph F. Rosati, Tina M. Davis, Tricia B. Reilly and Elizabeth Sweeny, attorney Sarah Klein-Cloud and counsel Dan Anderson; antitrust partner Elai Katz, counsel Lauren Rackow and associate Emily Lentz; environmental associates Peter J. Gioello and Lynn R. Schmidt; executive compensation and benefits counsel Mark J. Gelman; intellectual property counsel Alexander M. Kim and associate Kenneth Ritz; regulatory associate Peter T. Mazzone; and tax partner Craig M. Horowitz and associate Samir Kurani.